Augtyro (repotrectinib) — United Healthcare
solid tumors with neurotrophic tyrosine receptor kinase (NTRK) gene fusion
Initial criteria
- Presence of solid tumor(s)
- Disease is positive for neurotrophic tyrosine receptor kinase (NTRK) gene fusion (e.g., ETV6-NTRK3, TPM3-NTRK1, LMNA-NTRK1, etc.)
- Disease is locally advanced OR metastatic OR unresectable
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Augtyro therapy
Approval duration
12 months